TLR4-Mediated Pathway Triggers Interferon-Independent G0 Arrest and Antiviral SAMHD1 Activity in Macrophages by Mlcochova, Petra et al.
ReportTLR4-Mediated Pathway Triggers Interferon-
Independent G0 Arrest and Antiviral SAMHD1
Activity in MacrophagesGraphical AbstractHighlightsd TLR4 activation mediates TRIF-dependent G0 arrest in
human primary macrophages
d G0 arrest regulates phosphorylation and antiretroviral activity
of SAMHD1
d SAMHD1 is responsible for the IFN-independent HIV-1
blockade after TLR4 activation
d Whole gram-negative bacteria induce IFN-independent G0
arrest in human MDMsMlcochova et al., 2020, Cell Reports 30, 3972–3980
March 24, 2020 ª 2020 The Author(s).
https://doi.org/10.1016/j.celrep.2020.03.008Authors





Mlcochova et al. demonstrate that TLR4
activation regulates the cell cycle in
human primary macrophages. This
culminates in G0 arrest and activation of
the antiviral protein SAMHD1, suggesting
that macrophages can achieve a
heightened state of alert in response to
pathogen-associated danger signals in
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Macrophages exist predominantly in two distinct
states, G0 and a G1-like state that is accompanied
by phosphorylation of SAMHD1 at T592. Here, we
demonstrate that Toll-like receptor 4 (TLR4) activa-
tion can potently induce G0 arrest and SAMHD1 an-
tiretroviral activity by an interferon (IFN)-independent
pathway. This pathway requires TLR4 engagement
with TRIF, but not involvement of TBK1 or IRF3.
Exclusive Myd88 activators are unable to trigger G0
arrest or SAMHD1 dephosphorylation, demon-
strating this arrest is also Myd88/nuclear factor kB
(NF-kB) independent. The G0 arrest is accompanied
by p21 upregulation and CDK1 depletion, consistent
with the observed SAMHD1 dephosphorylation at
T592. Furthermore, we show by SAMHD1 knock-
down that the TLR4-activated pathway potently
blocks HIV-1 infection in macrophages specifically
via SAMHD1. Together, these data demonstrate
thatmacrophages canmobilize an intrinsic cell arrest
and anti-viral state by activating TLR4 prior to IFN
secretion, thereby highlighting the importance of
cell-cycle regulation as a response to pathogen-
associated danger signals in macrophages.
INTRODUCTION
Macrophages are the first line of defense against invading path-
ogens, sensing through pathogen recognition receptors (PRRs)
and initiating innate and adaptive responses. The most studied
PRRs are Toll-like receptors (TLRs), expressed in monocytes,
macrophages, and dendritic cells. They play a fundamental
role in recognition of pathogen-associated molecular patterns
expressed on infectious agents and subsequently initiate a se-
ries of inflammatory events that depend upon the MyD88 and/or
TRIF signaling pathways (Iwasaki and Medzhitov, 2004). The
MyD88-dependent pathway is activated by all TLRs except
TLR3 that signals only through TRIF. TLR4, however, activates
both MyD88- and TRIF-dependent pathways in response to
lipopolysaccharide (LPS), a component from the wall of3972 Cell Reports 30, 3972–3980, March 24, 2020 ª 2020 The Autho
This is an open access article under the CC BY license (http://creativegram-negative bacteria (Park and Lee, 2013); LPS-induced
TLR4/TRIF-dependent signaling results in TBK1 activation,
translocation of IRF3 into the nucleus, and type I IFN production,
whereasMyD88-dependent signaling results in nuclear factor kB
(NF-kB) translocation and expression of various pro-inflamma-
tory genes (Akira and Takeda, 2004; Kawai et al., 2001).
Macrophages, cells normally residing in a G0/terminally differ-
entiated state, can re-enter the cell cycle into a G1-like phase, ex-
pressing certain cellular cell-cycle factors (Mlcochova et al., 2017,
2018), including cyclin-dependent kinase 1 (CDK1). This kinase is
known to phosphorylate and deactivate the antiviral activity of
SAMHD1 (Cribier et al., 2013; White et al., 2013), a
deoxynucleotide-triphosphate (dNTP) hydrolase that restricts
HIV-1 (Arnold et al., 2015; Goldstone et al., 2011; Hrecka et al.,
2011;Laguetteet al., 2011;Lahouassaetal., 2012).SAMHD1phos-
phorylation at position T592 has been shown to be mediated by
CDK1/2 (Cribier et al., 2013; White et al., 2013). Some argue that
SAMHD1phosphorylation at position T592 impairs its dNTPhydro-
lase activity and allows viral DNA synthesis to occur (Arnold et al.,
2015), whereas others propose that T592 phosphorylation does
not regulate SAMHD1 dNTPase activity and/or that T592
phosphorylation impacts dNTPase-independent restriction mech-
anisms (Bhattacharyaetal., 2016;Herrmannetal., 2018;Valle-Cas-
uso et al., 2017; Welbourn and Strebel, 2016; White et al., 2013).
Type I interferons (IFNs) are known to arrest cycling cells (Xaus
et al., 1999; Zhang et al., 2007) and lead to dephosphorylation/acti-
vation of SAMHD1 in monocyte-derived macrophages (MDMs)
(Cribier et al., 2013; Szaniawski et al., 2018), although the mecha-
nism is unclear. LPS has known potent inhibitory activity against
HIV-1 infection (Bernstein et al., 1991; Franchin et al., 2000; Geo-
nnotti et al., 2010; Kornbluth et al., 1989; Reinhard et al., 2014;
Schlaepfer et al., 2014; Verani et al., 2002), partly due to downregu-
lation of receptors for HIV-1 entry and impairment of early steps of
the viral life cycle (Franchin et al., 2000; Verani et al., 1997; Wang
etal., 2008).ThemediatorsofHIV-1suppressionbyLPS-stimulated
MDMs are mostly secreted b-chemokines and IFNs (Geonnotti
et al., 2010; Schlaepfer et al., 2014; Verani et al., 1997, 2002). How-
ever, some data suggest that IFN release by LPS-stimulated mac-
rophages/dendritic cells might not be the main mediator of HIV-1
suppression (Reinhard et al., 2014; Verani et al., 2002), although
the underlying mechanism has not been elucidated.
Here we show that TLR4 activation by LPS and whole bacteria
can regulate transition between G1 and G0 and SAMHD1 antiviralr(s).
commons.org/licenses/by/4.0/).
activity via aMyd88-and IFN-independent pathway.Weshow that
the G1-to-G0 transition is downstream of TRIF but completely in-
dependent fromTBK1 and IRF3 activation. The resultingG0 arrest
is accompanied by p21 upregulation and SAMHD1 dephosphory-
lation. This demonstrates that TLR4 activation can directly induce
G0 arrest in human macrophages independent of IFN secretion,
while activating a pathogen defense program mediated by
SAMHD1. This work adds to growing evidence that G0 arrest is
a conserved and important response to danger signals even in
cells classically viewed as being terminally differentiated.
RESULTS
TBK1- and IFN-Independent G0 Arrest following TLR4
Engagement by LPS Activates SAMHD1 Antiretroviral
Activity
We have shown previously that macrophage transition from G0
to a G1-like state is accompanied by an increase in certain
cell-cycle-associated proteins, such as MCM2 and CDK1, as
well as phosphorylation of SAMHD1 at T592 that confers
increased susceptibility to HIV-1 infection (Mlcochova et al.,
2017, 2018). Although the cell-cycle state ofmacrophages in vivo
is poorly defined, we demonstrated that two widely accepted
in vitro MDM differentiation protocols that differ in what type of
culture media is used can lead to differences in the proportion
of MDMs in G1 (Figure S1). MDMs differentiated in human serum
(HS) are mainly in G0 (94%), and those differentiated in fetal
calf serum (FCS) are predominantly in G1 (70%) (Figure S1C),
whereas hierarchical clustering of whole genome expression
data showed that HS- and FCS-cultured MDMs cluster together
and are distinct from closely related myeloid cells (Mlcochova
et al., 2017). Further, in case of HS differentiation (mostly G0
MDMs), SAMHD1 is dephosphorylated/active. In case of FCS
differentiation (MDMs mostly in G1), SAMHD1 is phosphory-
lated/inactive (Figures S1A and S1F–S1H). In the present study,
we used the FCS differentiation protocol (Figure S1).
Treatment with 10 ng/mL LPS for 18 h resulted in a decrease of
MCM2andCDK1expressionand asexpected, SAMHD1dephos-
phorylation at T592 (Figures 1A and S1I–S1K). These results sug-
gest that LPS treatment led to G1-to-G0 transition (G0 arrest)
in macrophages where SAMHD1 is activated and can block HIV-
1 infection as shown in Figure 1A. Of note, HS-differentiatedmac-
rophages behaved in a similar way following LPS exposure
(Figure S1E). Crucially, the TLR4 inhibitor TAK242 completely pre-
vented G0 arrest and SAMHD1 phosphorylation changes,
restoring HIV-1 infection (Figures 1A–1C). Blocking IFN signaling
in macrophages by treatment with the JAK1/2 inhibitor ruxolitinib
(RUXO) could not prevent G1-to-G0 transition, demonstrating
thatLPS-inducedG0arrestandSAMHD1dephosphorylation/acti-
vation in human macrophages via TLR4 is IFN independent.
We next used the TBK1 inhibitor BX795 that blocks phosphory-
lation, nuclear translocation, and transcriptional activity of IRF3.
This drug successfully prevented IRF3 translocation to the nucleus
(Figure 1C), but could not preventG1-to-G0 transitioning, SAMHD1
dephosphorylation, and blockade of HIV-1 infection (Figures 1A–
1C). Similarly, TBK1 knockdown (KD) was unable to prevent
G1-to-G0 transitioning (Figures 1D–1H). By contrast, depletion of
TRIF did prevent G1-to-G0 transitioning (Figures 1D–1H), revealingthat G0 arrest following TLR4 activation is downstream of TRIF but
upstream of TBK1 signaling (Figures 1B and 1D–1H).
MyD88 Activation via TLR4 or TLR5 Does Not Induce G0
Arrest
Tenascin-C (TNC) is anextracellularmatrix protein rapidly induced
at the site of infection or injury, where it triggers inflammation by
activating TLR4 in different cells, including macrophages (Mid-
wood et al., 2016). This TLR4 activation is specifically mediated
through the MyD88-dependent pathway (Midwood et al., 2009)
(Figure 2A). Flagellin (FLA) is the main component of bacterial fla-
gellum. It binds toTLR5and inducesMyD88-dependent signaling.
Both TNC and FLA effectively activated the MyD88-dependent
pathway inMDMs, whichwas confirmed by detectable transloca-
tion of NF-kB and production of cytokines (interleukin-6 [IL-6],
IL-8) into culture media, but absence of nuclear IRF3 and
CXCL10 production (Figures 2B and 2C). Importantly, when
MDMs were treated with TNC or FLA, no changes to cell-cycle
protein expression, SAMHD1 phosphorylation, or HIV-1 inhibition
were detected (Figure 2D). From these experiments we conclude
that MyD88 activation is insufficient to induce G0 arrest, dephos-
phorylation of SAMHD1, and blockade of HIV-1 infection.
LPS Activation of TLR4 Results in IFN-Independent
Upregulation of p21
We hypothesized that the LPS-induced IFN-independent G0
arrest would be regulated by expression of negative cell-cycle
regulators, such as p16, p21, or p27. Immunoblots performed in
the presence of RUXO to block IFN-dependent signaling
confirmed that the decrease in CDK1 and MCM2 after LPS treat-
ment was accompanied by increased p21 levels (Figure 3A).
Because we were unable to detect p27 or p16 expression in
immunoblot, we next sought to further characterize the cell-
cycle program changes triggered by LPS in MDMs, using a panel
of cell-cycle-associated transcripts measured by qPCR (Figures
3B and S2A–S2D). Statistically significant decreases compared
with the untreated control (set to 1) were observed in the following
transcripts associated with cell-cycle progression: CDK1; MCM2;
and cyclins E2, B1, E1, A2, and E2F1. A significant increase was
observed for p21 transcript associated with cell-cycle arrest (Fig-
ure 3C, far right panel). The full panel of transcripts is shown in
Figures S2A–S2D. It has been suggested that production of reac-
tive oxygen species (ROS) or DNA damage during LPS treatment
can activatep21 pathway and cell-cycle arrest in proliferating cells
(Cheng et al., 2015; Mytych et al., 2017). In our study, exposure to
LPS led to increased p21 expression, but not to markers associ-
ated with DNA damage, such as gH2AX and 53BP1 (Figures
S3A–S3D). LPS triggered ROS production (Figure S3E) that could
be inhibited by using N-acetyl-cysteine (NAC). Nevertheless, this
inhibition had no effect on LPS-mediated G0 arrest (Figure S3F).
Our data thus suggest that ROS or DNA damage is unlikely to
be responsible for G0 arrest in human MDMs.
Redundancy of Pathways Activated by TLR4 that Lead to
G0 Arrest
IFN as a cause of cell-cycle arrest has been reported in myeloid
cells frommice andmurine cell lines, as well as in human cell lines
(Dey et al., 2000; Xaus et al., 1999; Zhang et al., 2007),monocytes,Cell Reports 30, 3972–3980, March 24, 2020 3973
Figure 1. TLR4 Activation Induces G0 Arrest, Dephosphorylates SAMHD1, and Blocks HIV-1 Infection in an Interferon-Independent Manner
(A) MDMs were treated with TAK242, BX795, and RUXO 6 h before addition of LPS. Cells were infected by vesicular stomatitis virus G protein (VSV-G)-pseu-
dotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-infection (n = 5, mean ± SEM). Cells from a representative donor were used
for immunoblotting.
(B) A simplified diagram of TLR4 signaling in response to LPS. LPS activates bothMyD88-dependent and -independent signaling pathways. BX795, an inhibitor of
TBK1; RUXO (ruxolitinib), an inhibitor of JAK1/2 kinase that suppresses IFN signaling; TAK242, an inhibitor of TLR4 signaling.
(C) IRF3/NF-kB nuclear translocation assay. Cells were exposed to LPS in the absence or presence of TAK242, BX795, and RUXO, and 2 h later stained for
IRF3/NF-kB. The percentage of cells with nuclear staining was determined (n = 3, mean ± SEM). Scale bars, 20 mm.
(D) Expression data of TRIF and TBK1 in MDMs, displayed as cycle threshold (Ct) values (n = 3, mean ± SEM).
(E–H) MDMs were transfected with control or TRIF, TBK1 siRNA. mRNA expression is shown as fold change relative to control (n = 3, mean ± SEM) (E). Cells from
a representative donor were used for immunoblotting (F). Cells were exposed to LPS in control or KD cells, and 2 h later stained for IRF3/NF-kB. % of cells with
nuclear staining was determined (n = 3, mean ± SEM) (G). MDMs transfected with control or TRIF, TBK1 siRNA were treated with LPS. Cells were infected
by VSV-G-pseudotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-infection (n = 3 donors, mean ± SEM). Cells from a
representative donor were used for immunoblotting (H).
***p % 0.001; **p % 0.01; *p % 0.1; nsp, non-significant, paired t test.and T cells (Munn et al., 1996). We next examined the effect of
blocking IFN signaling after TLR4 activation, as well as after addi-
tion of exogenous IFNb (Figures S2C–S2F). RUXO, an inhibitor of
JAK kinases and IFN signaling, was used to treat MDM 6 h before
addition of LPS or IFNb. As expected, RUXO completely blocked
expression of selected interferon stimulated genes (ISGs),3974 Cell Reports 30, 3972–3980, March 24, 2020CXCL10,MxA, ISG 54, and ISG 56, after both LPS and IFNb treat-
ment, confirming that IFN signaling is inhibited in both conditions
(Figures S2C).
AlthoughG0arrestwasobservedafter bothLPSandexogenous
IFNbaddition, basedonexpression levels of cell-cycle-associated
transcripts and protein expression of cell-cycle marker MCM2,
Figure 2. TLR4-Mediated Activation of SAMHD1 Is MyD88 Independent
(A) Diagram of TLR4 activation. LPS activates both MyD88-dependent and -independent signaling pathways. Tenascin-C (TNC) and Flagellin (FLA) activate only
the MyD88-dependent pathway leading to NF-kB translocation into the nucleus.
(B) IRF3/NF-kB translocation assay. Cells were exposed to TNC, FLA, and LPS and 2 h later stained for IRF3/NF-kB. The percentage of cells with nuclear staining
was determined (n = 3, mean ± SEM). Scale bars, 20 mm.
(C) MDMs were treated with LPS, TNC, and FLA, and cytokines were measured by ELISA in culture media 24 h later.
(D) MDMs treated with TNC, FLA, and LPS were infected by VSV-G-pseudotyped HIV-1 18 h later. The percentage of infected cells was determined 48 h post-
infection (n = 3, mean ± SEM). Cells from a representative donor were used for immunoblotting.
***p % 0.001; **p % 0.01; nsp, non-significant, paired t-test.RUXO was unable to rescue this arrest caused by LPS/TLR4
activationbut completely rescuedG0arrest after additionof exog-
enous IFNb (Figures S2C–S2E). This confirms redundancy of
pathwaysactivatedbyTLR4that lead toG0arrest. Inconcordance
with these results, RUXO failed to restore HIV-1 infection from the
effect of LPS but completely rescued HIV-1 infection after expo-
sure to exogenous IFNb (Figure S2E). These data were confirmed
by using an IFN receptor antibody instead of RUXO (Figure S2F).
As a control, the TLR4 inhibitor TAK242 prevented G0 arrest and
restored HIV-1 infection after LPS treatment. As expected,
TAK242could not rescue either after IFNb treatment.Weconclude
the existence of two independent pathways that are responsible
for G0 arrest in MDMs, both of which are able to potently block
HIV-1 infection. The first and early block of HIV-1 infection is via
G0 arrest, whereas IFN production represents a second wave.
SAMHD1 Is Directly Responsible for the IFN-
Independent HIV-1 Blockade following TLR4 Activation
We have shown previously that the restriction of HIV-1 infection
in G0 MDMs can be completely lifted by SAMHD1 depletion(Mlcochova et al., 2017). In the present study, the experimental
system involves use of MDMs predominantly in G1-like state,
where SAMHD1 is deactivated/phosphorylated at T592.
To confirm that LPS-mediated SAMHD1 activation/dephosphor-
ylation is responsible for block to HIV-1 infection during IFN-in-
dependent G0 arrest, we employed SAMHD1KD in the presence
of RUXO to inhibit the effects of any secreted IFN (Figures 3D and
3E). We knocked down SAMHD1 expression in human MDMs
using small interfering RNA (siRNA) and infected MDMs in the
presence or absence of LPS in four different donors (Figures
3D and 3E). SAMHD1 KD lifted HIV-1 block in the presence of
LPS. Immunoblot confirmed 80% SAMHD1 KD with no effect
on the cell-cycle marker MCM2 (Figure 3E).
In order to confirm the role of SAMHD1, we employed Vpx, an
accessory protein encoded by lentiviruses such as HIV-2 and
simian immunodeficiency virus (SIV), but not HIV-1 (Hrecka
et al., 2011; Laguette et al., 2011). Vpx degrades SAMHD1 in a
DCAF-dependent fashion (Hrecka et al., 2011). We exposed
MDMs to LPS and co-infected cells 18 h later with HIV-1 and
SIVmac virus-like particles (SIV VLPs) bearing Vpx (wild-typeCell Reports 30, 3972–3980, March 24, 2020 3975
Figure 3. Cell-Cycle Profiling of MDMs following TLR4 Activation and Demonstration that SAMHD1 Mediates the Interferon-Independent
Blockade of HIV Infection
(A) MDMswere treated with RUXO 6 h before addition of LPS. Cells from a representative donor were used for immunoblotting 18 h later to detect changes in cell-
cycle-associated proteins.
(B) A heatmap depicts differential gene expression patterns of cell-cycle-associated transcripts in MDMs treated with LPS in the presence of RUXO in three
donors. The color scale bar corresponds to log-fold expression.
(C) Relative expression levels (fold changes) of statistically significantly changed cell-cycle-associated transcripts after LPS in the presence of RUXO (n = 4
donors, mean ± SEM).
(D and E) MDMswere transfectedwith control or pool of SAMHD1 siRNAs (KD) and 3 days later treatedwith RUXO and followed 6 h after that with LPS. Cells were
infected in the presence of LPS with VSV-G-pseudotyped HIV-1 GFP 18 h later. The percentage of infected cells was quantified 48 h post-infection. SAMHD1 KD
in four different donors. Error bars represent technical triplicates (D). Cells from a representative donor were used for immunoblotting (E).
(F) Immunoblot of SIV virus-like particles (VLPs). delX, SIV VLP with deleted Vpx; E16A, SIV VLP containing mutated Vpx (E16A mutant Vpx does not bind
SAMHD1); WT, SIV VLP containing wild-type Vpx.
(G) SAMHD1 degradation in MDMs by SIV VLPs. Equal quantities of SIV VLPs were added to macrophages. Cells from a representative donor were used for
immunoblotting.
(H) MDMs were treated ± LPS and infected by VSV-G-pseudotyped HIV-1 in the presence of different SIV VLPs (as indicated). The percentage of infected cells
was determined 48 h post-infection (n = 4 donors, mean ± SEM).
(I) Diagram of G0 arrest following TLR4/TRIF activation resulting in block to HIV-1 infection.
***p % 0.001; **p % 0.01; *p % 0.1; nsp, non-significant, paired t test.[WT], degrades SAMHD1), no Vpx present (delX, no SAMHD1
degradation), and E16A Vpx mutant that fails to interact with
SAMHD1 (Ahn et al., 2012) (E16A, no SAMHD1 degradation)3976 Cell Reports 30, 3972–3980, March 24, 2020(Figures 3F and 3G). When MDMs were exposed to LPS and in-
fected with HIV-1, only cells where SAMHD1 was exogenously
depleted by co-infection with SIV VLP WT were fully susceptible
Figure 4. TLR4 Activation by Whole E. coli Induces Interferon-Independent G0 Arrest
(A) pHrodo-labeled E. coliwere added toMDMs for 1 h. MDMswere washed and fixed. 104 cells were recorded and analyzed. Percentage of E. coli-positive cells
was determined using automated cell imaging system Hermes WiScan and ImageJ.
(B) IRF3/NF-kB translocation assay. Cells were exposed to pHrodo E. coli in the presence or absence of inhibitors and 2 h later stained for IRF3/NF-kB. The
percentage of cells with nuclear staining was determined (n = 3, mean ± SEM). No IRF3 or NF-kB translocation was detected in un-treated cells.
(C and D) MDMs were treated with (C) TAK242 or RUXO 6 h or (D) BX795 2 h before addition of pHrodo E. coli. Cells were infected by VSV-G-pseudotyped HIV-1
18 h later. The percentage of infected cells was determined 48 h post-infection (n = 3 donors, mean ± SEM). Cells from a representative donor were used for
immunoblotting.
(E and F) Relative expression levels (fold changes) of ISGs (E) and cell-cycle-associated transcripts (F). MDMs were treated with RUXO 6 h before addition of
pHrodo E. coli. Cells were collected 24 h later (n = 3 donors, mean ± SEM).
(G) Diagram of G0 arrest following exposure to E. coli and TLR4/TRIF activation resulting in block to HIV-1 infection.
***p % 0.001; **p % 0.01; *p % 0.1, paired t test.to infection (Figure 3H). These data highlight the key role that
SAMHD1 plays in the TLR4-mediated IFN-independent antire-
troviral state in human macrophages (Figure 3I).
Whole Gram-Negative Bacteria Induce IFN-Independent
G0 Arrest in Human MDMs
We employed pHrodo E. coli BioParticles to activate TLR4 by
whole E. coli bacteria. BioParticles were incubated with MDMs
in the presence or absence of different inhibitors for 1 h at
37C (Figure 4A). Unbound pHrodo was washed off, andmacrophages were incubated overnight. Cell supernatants
were then collected for cytokine detection (Figure S4A), and
MDMs were infected with HIV-1. First, phagocytosis of pHrodo
was unaffected by the presence of TLR4, JAK1/2, or TBK1 inhib-
itors (Figure 4A). Second, binding/ingestion of pHrodo triggered
expression of tumor necrosis factor alpha (TNF-a), IL-6, and IL-8
that was abrogated after TLR4 inhibition, but not by inhibition of
the IFN signaling pathway (Figure S4A). This was confirmed by
IRF3 and NF-kB translocation assays (Figure 4B). These data
show that pHrodo triggers a robust immune response inCell Reports 30, 3972–3980, March 24, 2020 3977
MDMs that can be prevented by TLR4 inhibition. Treatment of
MDMs with pHrodo induced potent HIV-1 inhibition that was
accompanied by G0 arrest and SAMHD1 activation/dephos-
phorylation at T592 (Figures 4C and 4D). Importantly, TLR4
blockade was able to prevent G0 arrest, SAMHD1 dephosphor-
ylation, and HIV-1 blockade, but neither RUXO nor TBK1 inhibi-
tor BX795 could achieve this, phenocopying experiments with
LPS alone (Figure 1). However, when we measured cell-cycle-
associated transcripts there were several differences between
LPS- and E. coli-mediated TLR4 activation, mostly connected
to negative regulators of cell cycle. p16 and WIF1 were signifi-
cantly increased, but no change was detected for p21 (Figures
4E, 4F, and S4B). These data show that gram-negative bacteria
can induce IFN-independent G0 arrest and SAMHD1 dephos-
phorylation/activation in human macrophages (Figure 4G).
DISCUSSION
Herewehaveshown thatmacrophages respond togram-negative
bacteria not only by activating the canonical TLR4 pathways
involving NF-kB and IRF3, but also by a pathway independent of
TBK1 and IRF3, culminating in p21 upregulation and G0 arrest.
This previously unrecognized pathway is not dependent or sensi-
tive to blockade of the type I IFN/JAK-STAT signaling axis. Activa-
tion of the pathway leads to dephosphorylation of SAMHD1 at a
T592 and a specific block to HIV-1 infection that is significantly
counteracted by SAMHD1 depletion. Importantly, we have also
shown that TLR4 activation by whole E. coli bacteria also leads
to a similar IFN-independent G0 arrest in human macrophages.
The effect of LPS on cell cycle has been reported in mouse pri-
mary cells and murine cell lines (Vairo et al., 1992; Zhang et al.,
2017) or in the human cell line, THP-1/U937 (Mytych et al., 2017;
Thongngarm et al., 2003). Despite these reports, surprisingly little
is known about the mechanism how LPS causes cell-cycle arrest.
It has been reported that LPS treatment leads top21pathway acti-
vation and cell-cycle arrest in monocytic THP-1 (Mytych et al.,
2017). In addition, LPS exposure has been linked to ROS produc-
tion, subsequent DNA damage, and upregulation of p21 expres-
sion in monocytes and fibroblasts (Cheng et al., 2015; Mytych
et al., 2017). Despite these reports, our data show that neither
ROSnorDNAdamageseem tobe associatedwithG0arrest in hu-
manMDMs(FigureS3).Anotherpossibility is thatstrongTLR4acti-
vation triggers an apoptotic program in the cells, and cell-cycle ar-
rest is the first step toapoptosis andcell death (EvanandVousden,
2001). However, our data do not support this hypothesis because
no significant reduction in cell numberswas observedup to 5 days
post-LPS treatment (Figure S3G), suggesting survival of activated
macrophages. Furthermore, we observed increased levels of p21
after LPS treatment, and p21 has been reported to play an antia-
poptotic role (Benson et al., 2009; Gartel and Tyner, 2002;
Merched and Chan, 2004). Increased expression of p21 might
thus lead to G0 arrest but at the same time prevent apoptosis.
Whywouldmacrophages regulate their cell cycle in response to
bacteria?Macrophages are secretory cells vital to the regulationof
immune responses and development of inflammation. Even
though our previous work showed that MDMs enter G1 without
measurable cell division (Mlcochova et al., 2017),many tissue resi-
dentmacrophagescanproliferate (GomezPerdigueroetal., 2013).3978 Cell Reports 30, 3972–3980, March 24, 2020One can imagine that cell division of macrophages would benefit
the host by increasing the number of effector cells at the center
of infection. However, the division of infected cells harboring live
pathogen could also lead to doubling of infected cells, an event
that can potentially harm the host. Therefore, we speculate that
this early cell arrest could be a mechanism for limiting local inva-
sion of gram-negative bacteria into macrophages.
It is also possible that cell-cycle changes are necessary for
activation of alternative functions of cell-cycle-associated pro-
teins. G0 or cell-cycle arrested cells will increase expression of
p14, p16, p21, or p27 proteins, for example. It has been shown
that p21 can suppress IL-1b (Scatizzi et al., 2009), or that p16 in-
hibits macrophage activity by degradation of IL-1 receptor and
thus impairs IL-6 production (Murakami et al., 2012). In addition,
previous studies have shown that deficiency in p21 renders mice
more susceptible to septic shock (Scatizzi et al., 2009; Trakala
et al., 2009); therefore, cell arrest may be a mechanism for
limiting production of potentially harmful cytokines.
The relevance of macrophage G0 arrest by LPS may be rele-
vant in HIV pathogenesis, where macrophages will be exposed
to gut-derived LPS during inflammation in the acute or chronic
phase of HIV. It has been shown that circulating LPS is increased
in chronically HIV-1-infected individuals and SIV-infected non-
human primates (Brenchley et al., 2006). Exploring LPS-medi-
ated regulation in primary human macrophages is therefore
important for our understanding of HIV-1 replication and cellular
reservoirs (Watters et al., 2013).
Our study is based on primary MDMs rather than tissue-
derivedmacrophages, such as those in lymphnodes, gut, or cen-
tral nervous system.We utilized a differentiation protocol that led
to high proportions of macrophages in G1 in order to be able to
clearly study the effect of LPS on cell cycle. Although we previ-
ously reported 10%–20% of ex vivo peritoneal mouse macro-
phages and microglial cells to be in G1 (Mlcochova et al.,
2017), it is difficult to know the proportions of macrophages in
G1 across diverse human tissues. Even if 10%–20% of macro-
phages in vivo are in G1, this is nonetheless significant, and
LPS responses in these cells warrant specific characterization.
In summary,our datashow thatTLR4activationbyLPSorwhole
bacteria regulates the cell cycle in human primary macrophages
through a non-canonical mechanism that is TRIF dependent.
This culminates in G0 arrest and activation of the antiviral protein
SAMHD1, suggesting that macrophages can rapidly achieve a
heightened state of alert in response to gram-negative bacteria
prior to type I IFN secretion. Finally, given that macrophage G0
arrest occurs followingDNAdamage (Mlcochova et al., 2018), his-
tone deacetylase (HDAC) inhibition (Mlcochova et al., 2017), and
immune stimuli, we conclude that cell-cycle regulation appears
to be a conserved and important response to danger signals in hu-
man macrophages.STAR+METHODS
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membrane
GE Healthcare #10600023LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prof. Ravi
Gupta (rkg20@cam.ac.uk).
This study did not generate unique new reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and viruses
293T cells were cultured in DMEM complete (DMEM supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS).
VSV-G HIV-1 GFP virus was produced by transfection of 293T with GFP-encoding genome CSGW, packaging plasmid p8.91 and
pMDG as previously described (Besnier et al., 2002). SIVmac Virus like particles (VLP) containing Vpx were prepared as previously
described (Goujon et al., 2008; Reinhard et al., 2014).
Monocyte isolation and differentiation
PBMC were prepared from HIV seronegative male and female donors (after informed consent was obtained), by density-gradient
centrifugation (Lymphoprep, Axis-Shield, UK). Monocyte-derived macrophages (MDM) were prepared by adherence with washing
of non-adherent cells after 2h, with subsequent maintenance of adherent cells in RPMI 1640medium supplemented with 10%human
serum andMCSF (10ng/ml) for 3 days and then differentiated for a further 4 days in RPMI 1640medium supplemented with 10% fetal
calf sera without M-CSF.
Ethics Statement
Adult subjects provided written informed consent. Primary Macrophage & Dendritic Cell Cultures from Healthy Volunteer Blood
Donors has been reviewed and granted ethical permission by the National Research Ethics Service through The Joint UCL/UCLH
Committees on the Ethics of Human Research (Committee Alpha) 2nd of December 2009. Reference number 06/Q0502/92.
METHOD DETAILS
Infection of primary cells using full-length and VSV-G pseudotyped HIV-1 viruses
GFP containing VSV-G pseudotyped HIV-1 was added to MDM and after 4h incubation removed and cells were washed in culture
medium. The percentage of infected cells was determined 48h post-infection by Hermes WiScan automated cell-imaging system
(IDEA Bio-Medical Ltd. Rehovot, Israel) and analyzed using MetaMorph and ImageJ software. In the experiments when LPS was
used cells were stimulated with 10ng/ml of LPS 18h before infection unless stated otherwise. 104 cells were recorded and analyzed.e4 Cell Reports 30, 3972–3980.e1–e5, March 24, 2020
SDS-PAGE and Immunoblots
Cells were lysed in reducing Laemmli SDS sample buffer containing PhosSTOP (Phosphatase Inhibitor Cocktail Tablets, Roche,
Switzerland) at 96C for 10 minutes and the proteins separated on NuPAGE Novex 4%–12% Bis-Tris Gels. Subsequently, the
proteins were transferred onto PVDF membranes (Millipore, Billerica, MA, USA), the membranes were quenched, and proteins
detected using specific antibodies. Labeled protein bands were detected using Amersham ECL Prime Western Blotting Detection
Reagent (GE Healthcare, USA) and Amersham Hyperfilm or AlphaInnotech CCD camera. Protein band intensities were recorded
and quantified using AlphaInnotech CCD camera and AlphaView software (ProteinSimple, San Jose, California, USA).
SAMHD1 knock-down by siRNA
1x10e5 MDM differentiated in MCSF for 4 days were transfected with 20pmol of siRNA (L-013950-01, Dharmacon) using Lipofect-
amine RNAiMAX Transfection Reagent (Invitrogen). Transfection medium was replaced after 18h with RPMI 1640 medium
supplemented with 10% FCS and cells cultured for additional 3 days before infection.
Quantitative PCR
Total RNA was isolated from macrophages using the Total RNA Purification Kit from Norgen Biotek (Thorold, Canada). cDNA was
synthesized using Superscript III Reverse Transcriptase (Thermo Fisher Scientific) using 500ng of template RNA. qPCR was per-
formed on ABI 7300 machine (Thermo Fisher Scientific) using Fast SYRB green master mix (Thermo Fisher Scientific). Expression
levels of target genes were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as previously described (Tsang
et al., 2009). See primer sequences in STAR Methods.
Immunofluorescence
MDMswere fixed in 3%PFA, quenched with 50mMNH4Cl and permeabilized with 0.1% Triton X-100 in PBS or 90%Methanol. After
blocking in PBS/1% FCS, MDMs were labeled for 1 hour with primary antibodies diluted in PBS/1% FCS, washed and labeled again
with Alexa Fluor secondary antibodies for 1 hour. Cells were washed in PBS/1% FCS and stained with DAPI in PBS for 20 minutes.
Labeled cells were detected using Hermes WiScan automated cell-imaging system (IDEA Bio-Medical Ltd. Rehovot, Israel) and
analyzed using MetaMorph and ImageJ software. On average 104 cells were recorded and analyzed in each experiment.
Phagocytosis assay using pHrodo Bioparticles
MDM were exposed to 0.25ug pHrodo (a pH-sensitive, rhodamine-based dye)-labeled E. coli for 1h. MDM were washed 3x in PBS
and fixed. The percentage of E.coli positive cells was determined using Hermes WiScan automated cell-imaging system (IDEA Bio-
Medical Ltd. Rehovot, Israel) and analyzed using MetaMorph and ImageJ software. 104 cells were recorded and analyzed.
ELISA
Medium was collected and cytokine levels quantified by ELISA (BD Biosciences) according to the manufacturer’s instructions.
QUANTIFICATION AND STATISTICAL ANALYSIS
We have included number of replicates (equal to number of different donors), statistical tests, and significance criteria in figure leg-
ends and in the main text of the manuscript.
Statistical analysis was performed in Excel. We used the paired t test to determine significant differences. Following P values were
considered as significant: ***P value % 0.001, **P-value % 0.01, *P-value % 0.1
DATA AND CODE AVAILABILITY
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